Molteni Farmaceutici S.p.A

Molteni Farmaceutici S.p. was founded in 1892 by Giuseppe Molteni, a pharmacist, and entrepreneur who wanted to produce and distribute innovative medicines. The company is still family-owned and has its headquarters in Florence, Italy. According to its website, Molteni Farmaceutici S.p.A has a market cap of about $1.4B in May 2023 and employs more than 800 people.

The vision of Molteni Farmaceutici S.p.A is to improve the quality of life of patients by offering effective and safe solutions for their health needs. The company focuses on three main therapeutic areas: pain management, addiction treatment, and rare diseases. Some of the products that Molteni Farmaceutici S.p.A include opioids, naloxone, methadone, buprenorphine, and naltrexone.

Molteni Farmaceutici S.p.A is also involved in several research and development projects, both internally and in collaboration with other partners. For example, the company is working on a new formulation of naloxone for intranasal administration, which could be used to reverse opioid overdose more quickly and easily. Another project is the development of gene therapy for hemophilia A, a rare bleeding disorder caused by a lack of factor VIII.

Molteni Farmaceutici S.p.A has received several awards and recognitions for its achievements and contributions to the pharmaceutical industry. In 2019, the company won the Best Managed Companies award from Deloitte, which honors excellence in strategy, skills, innovation, culture, and governance. In 2020, the company was ranked among the top 100 Italian companies for sustainability by Il Sole 24 Ore, a leading business newspaper in Italy.

Foundation: 1892
Headquarters: Florence, Italy
Website: https://www.moltenifarma.it/